Lake Street Capital Issues Pessimistic Forecast for Treace Medical Concepts (NASDAQ:TMCI) Stock Price

robot
Abstract generation in progress

Lake Street Capital has lowered its price target for Treace Medical Concepts (NASDAQ:TMCI) to $7.00 from $7.50, despite maintaining a “buy” rating, indicating a significant potential upside. However, overall analyst sentiment for TMCI is negative, with a “Reduce” consensus rating and an average target price of $4.77, following multiple firms cutting their targets. The stock experienced an 11% drop to $1.66, and the company continues to face unprofitability with negative net margin and return on equity, even as its quarterly revenue slightly exceeded estimates.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin